Loading
A phase 1/2 trial of JAB-30355 in advanced solid tumours, run by Jacobio Pharmaceuticals Co., Ltd., now recruiting.
JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation is a phase 1/2 interventional study registered as NCT06386146 by Jacobio Pharmaceuticals Co., Ltd., with 144 participants planned, started 2024-07-24 and due to reach its primary completion in 2027-01. Interventions recorded: JAB-30355.
Shares Jacobio Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Jacobio Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Jacobio Pharmaceuticals and the tag pipeline.
Shares Jacobio Pharmaceuticals and the tag pipeline.
Shares Jacobio Pharmaceuticals and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.